
3D-Side closed a €2.7 million (~USD $2.71 million) Series C investment round. Funds will help strengthen the company’s position in the arthroplasty field, and support the launch of 3D-Cut and guides for corrective osteotomy and bone tumor resection in the U.S.
3D-Side develops and manufactures patient-specific surgical technology. Thanks to Artificial Intelligence and automation, 3D-Side provides high-quality simulations to plan joint replacement, osteotomy, tumor resection and cranial procedures. Its Customize software is approved under the CE Mark and also FDA 510(k)-cleared.
Khanh Tran Duy, CEO, said, “We are very pleased with the continued success of 3D-Side over the last few years. This new round of funding will allow us to continue to structure the company to meet new challenges and to develop its infrastructure to support its growth in the US in the years to come. We thank all our partners for believing in us and renewing their confidence in our team and our projects.”
Source: 3D-Side
3D-Side closed a €2.7 million (~USD $2.71 million) Series C investment round. Funds will help strengthen the company's position in the arthroplasty field, and support the launch of 3D-Cut and guides for corrective osteotomy and bone tumor resection in the U.S.
3D-Side develops and manufactures patient-specific surgical technology. Thanks to...
3D-Side closed a €2.7 million (~USD $2.71 million) Series C investment round. Funds will help strengthen the company’s position in the arthroplasty field, and support the launch of 3D-Cut and guides for corrective osteotomy and bone tumor resection in the U.S.
3D-Side develops and manufactures patient-specific surgical technology. Thanks to Artificial Intelligence and automation, 3D-Side provides high-quality simulations to plan joint replacement, osteotomy, tumor resection and cranial procedures. Its Customize software is approved under the CE Mark and also FDA 510(k)-cleared.
Khanh Tran Duy, CEO, said, “We are very pleased with the continued success of 3D-Side over the last few years. This new round of funding will allow us to continue to structure the company to meet new challenges and to develop its infrastructure to support its growth in the US in the years to come. We thank all our partners for believing in us and renewing their confidence in our team and our projects.”
Source: 3D-Side
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





